TY - JOUR
T1 - Sexually Transmitted Infection Prevalence among Women at Risk for HIV Exposure Initiating Safer Conception Care in Rural, Southwestern Uganda
AU - Chitneni, Pooja
AU - Bwana, Mwebesa Bosco
AU - Owembabazi, Moran
AU - O'Neil, Kasey
AU - Kalyebara, Paul Kato
AU - Muyindike, Winnie
AU - Musinguzi, Nicholas
AU - Bangsberg, David R.
AU - Marrazzo, Jeanne M.
AU - Haberer, Jessica E.
AU - Kaida, Angela
AU - Matthews, Lynn T.
N1 - Publisher Copyright:
© Lippincott Williams & Wilkins.
PY - 2020/8/1
Y1 - 2020/8/1
N2 - Background Knowledge of sexually transmitted infection (STI) prevalence and risk factors is important to the development of tenofovir-based preexposure prophylaxis (PrEP) and safer conception programming. We introduced STI screening among women at risk for HIV exposure who were participating in a safer conception study in southwestern Uganda. Methods We enrolled 131 HIV-uninfected women, planning for pregnancy with a partner living with HIV or of unknown HIV serostatus (2018-2019). Women were offered comprehensive safer conception counseling, including PrEP. Participants completed interviewer-administered questionnaires detailing sociodemographics and sexual history. We integrated laboratory screening for chlamydia, gonorrhea, trichomoniasis, and syphilis as a substudy to assess STI prevalence. Multivariable logistic regression was used to determine correlates. Results Ninety-four women completed STI screening (72% of enrolled). Median age was 30 (interquartile range, 26-34) years, and 94% chose PrEP as part of safer conception care. Overall, 24% had STIs: 13% chlamydia, 2% gonorrhea, 6% trichomoniasis, 6% syphilis, and 3% ≥2 STI. Sexually transmitted infection prevalence was associated with younger age (adjusted odds ratio [AOR], 0.87; 95% confidence interval [CI], 0.77-0.99), prior stillbirth (AOR, 5.04; 95% CI, 1.12-22.54), and not feeling vulnerable to HIV (AOR, 16.33; 95% CI, 1.12-237.94). Conclusions We describe a 24% curable STI prevalence among women at risk for HIV exposure who were planning for pregnancy. These data highlight the importance of integrating laboratory-based STI screening into safer conception programs to maximize the health of HIV-affected women, children, and families.
AB - Background Knowledge of sexually transmitted infection (STI) prevalence and risk factors is important to the development of tenofovir-based preexposure prophylaxis (PrEP) and safer conception programming. We introduced STI screening among women at risk for HIV exposure who were participating in a safer conception study in southwestern Uganda. Methods We enrolled 131 HIV-uninfected women, planning for pregnancy with a partner living with HIV or of unknown HIV serostatus (2018-2019). Women were offered comprehensive safer conception counseling, including PrEP. Participants completed interviewer-administered questionnaires detailing sociodemographics and sexual history. We integrated laboratory screening for chlamydia, gonorrhea, trichomoniasis, and syphilis as a substudy to assess STI prevalence. Multivariable logistic regression was used to determine correlates. Results Ninety-four women completed STI screening (72% of enrolled). Median age was 30 (interquartile range, 26-34) years, and 94% chose PrEP as part of safer conception care. Overall, 24% had STIs: 13% chlamydia, 2% gonorrhea, 6% trichomoniasis, 6% syphilis, and 3% ≥2 STI. Sexually transmitted infection prevalence was associated with younger age (adjusted odds ratio [AOR], 0.87; 95% confidence interval [CI], 0.77-0.99), prior stillbirth (AOR, 5.04; 95% CI, 1.12-22.54), and not feeling vulnerable to HIV (AOR, 16.33; 95% CI, 1.12-237.94). Conclusions We describe a 24% curable STI prevalence among women at risk for HIV exposure who were planning for pregnancy. These data highlight the importance of integrating laboratory-based STI screening into safer conception programs to maximize the health of HIV-affected women, children, and families.
UR - http://www.scopus.com/inward/record.url?scp=85088487648&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85088487648&partnerID=8YFLogxK
U2 - 10.1097/OLQ.0000000000001197
DO - 10.1097/OLQ.0000000000001197
M3 - Article
C2 - 32404858
AN - SCOPUS:85088487648
SN - 0148-5717
VL - 47
SP - E24-E28
JO - Sexually Transmitted Diseases
JF - Sexually Transmitted Diseases
IS - 8
ER -